| Field | Specification |
|---|---|
| Target | |
| Alternative names | Complement decay-accelerating factor;CD55;CD55;CR, DAF; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human CD55 recombinant protein (Position: D35-K347). Human CD55 shares 49.1% amino acid (aa) sequence identity with mouse CD55. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets complement decay-accelerating factor (gene CD55) in human samples and is validated for flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 41.4 kDa, and the supplier reports an observed band at about 75 kDa.
CD55, or decay-accelerating factor (DAF), is a GPI-anchored complement regulator on blood and many other cells. It speeds the breakdown of C3 and C5 convertases, protecting host cells from complement damage, and its loss on red cells contributes to paroxysmal nocturnal hemoglobinuria.
| Target | Complement decay-accelerating factor (gene CD55; UniProt P08174, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 41.4 kDa |
| Observed MW | 75 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human placenta tissue, human HeLa cells, human Caco-2 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human placenta tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with confirmed staining (ICC/IF): SiHa cells.
Samples with confirmed staining (ICC/IF): huamn placenta tissue.
Samples with a confirmed signal (flow cytometry): PC-3 cells, SiHa cells.
Immunogen
Recombinant human CD55 fragment (Asp35–Lys347), expressed in E. coli. Sequence identity with the mouse ortholog: 49.1%.
Reactivity Notes
The supplier lists reactivity with human. Tissue expression noted by UniProt (human): Expressed on the plasma membranes of all cell types that are in intimate contact with plasma complement proteins. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
